In the HER-2-low category, 52.6% had grade 3 or higher adverse events, while 12.1% developed ILD or pneumonia (20) Our findings revealed a lower occurrence of grade 3 or higher adverse events, with the majority of side effects being moderate (grades 1 or 2). The gene discussed is ERBB2; the disease is interstitial lung disease.